Lenea

Quick links to important sections

Lenea

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lenea

Quick Facts

Property Description
Active ingredient Ethinyl Estradiol, Gestodene
Form Oral Tablet
Pharmacological class Combined Oral Contraceptive (COC)
General use Prevention of pregnancy (Contraception)
Origin Synthetic (Steroidal hormones)

1. Lenea: Classification and Composition of the Oral Contraceptive

Lenea is a prescription-only, synthetic hormonal medicine administered as an oral tablet, and is classified as a Combined Oral Contraceptive (COC). This places it within the high-level pharmacological class of Hormonal Contraceptives, a category defined by the use of synthetic steroid hormones to regulate the reproductive cycle. Its specific combination product nature stems from the inclusion of two active ingredients: Ethinyl Estradiol, which functions as the estrogenic component, and Gestodene, which serves as the progestin. This formulation is designed for hormonal control. The product is intended for adult women seeking systemic regulation of their fertility.

2. Type of Contraception: Estrogen-Progestin Combination

The Estrogen-Progestin Combination in Lenea utilizes the complementary effects of both hormone types, distinguishing it from single-hormone alternatives. Gestodene is particularly notable as a synthetic third-generation progestin. This means it belongs to a modern class of progestins with a unique metabolic profile, making it a key differentiator within the COC category. The combination of ethinylestradiol and gestodene is a standard formulation for systemic contraception. This establishes the formulation as a method used to achieve birth control.

3. General Purpose of Lenea

The essential therapeutic purpose of Lenea is to provide contraception aimed at the prevention of pregnancy. This general benefit is achieved through the systemic action of the combined hormones, ensuring birth control for women of childbearing potential. The function of the medication is to maintain consistent control over the reproductive hormonal axis, a mechanism essential to its intended therapeutic outcome. A typical use scenario involves a woman using the product daily as her chosen method of reversible pregnancy prevention.

What side effects are possible with Lenea?

Lenea treatment is associated with a range of documented side effects, some of which are serious and require close medical monitoring as noted in regulatory labeling.

Serious and Clinically Significant Adverse Reactions

The most serious safety concerns identified in official prescribing information include:

  • Hypertension (High Blood Pressure): This is a very common side effect and can be severe. Blood pressure must be adequately controlled before starting treatment and monitored regularly.
  • Cardiac Dysfunction: Serious heart problems, including cardiac failure, have been reported. Clinical symptoms or signs of cardiac dysfunction should be monitored.
  • Hepatotoxicity (Liver Problems): Lenea can cause liver injury, which may lead to liver failure. Liver function tests must be checked before and periodically during therapy.
  • Renal Issues: This includes the potential for renal failure or impairment. Proteinuria (excess protein in the urine) is also a common and potentially serious adverse event that requires monitoring.
  • Gastrointestinal Complications: Severe and recurrent diarrhea is common. Less frequent but severe risks include the formation of fistulas and gastrointestinal perforation.
  • Arterial Thromboembolic Events: Blood clots in the arteries leading to events like stroke or myocardial infarction may occur.

Very Common Adverse Reactions

Based on clinical trial data, adverse reactions with a high incidence rate (e.g., ge30%) typically involve the following organ systems:

System-Organ Class Examples of Very Common Effects ( ge30%)
General/Systemic Fatigue, Decreased appetite, Decreased weight
Gastrointestinal Diarrhea, Nausea, Stomatitis, Vomiting
Vascular Hypertension
Musculoskeletal Arthralgia/Myalgia (Joint/Muscle Pain)

Population-Specific Safety Information

Due to the risk of fetal harm, Lenea is contraindicated for use during pregnancy. Females of reproductive potential must use effective contraception during treatment and for a specified period after the final dose. Similarly, women are advised not to breastfeed during treatment to avoid potential harm to the infant.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for an overdose of Lenea (Ethinyl Estradiol/Gestodene) consistently outlines a specific, non-life-threatening pattern of manifestations. The primary clinical signs documented in official prescribing information include nausea and vomiting. Furthermore, withdrawal bleeding may occur in females following the ingestion of doses exceeding the therapeutic regimen.

Severity and Emergency Action

Governmental sources generally classify this type of overdose as having a low risk of severe systemic toxicity, stating that no serious ill effects have been reported following acute ingestion of high doses. Despite the low-risk classification, regulatory authorities mandate that immediate medical attention must be sought for any suspected overdose event. This ensures professional evaluation and appropriate clinical observation.

Management and Population Considerations

Management of an overdose is defined as symptomatic and supportive treatment, as no specific antidote is known to exist. The official documentation also addresses accidental ingestion in specific populations. Overdose symptoms in pre-pubertal girls (children) are similar to those in adults, and the ingestion may also lead to withdrawal bleeding. The overall approach remains consistent with supporting the patient through the documented, self-limiting manifestations.

Therapeutic Uses of Lenea

What Lenea Treats: Main Uses and Benefits

The primary therapeutic purpose of Lenea (Ethinyl Estradiol/Gestodene) is to provide reversible oral contraception for women of childbearing potential. Beyond this use, Lenea is commonly used to help with conditions characterized by periods of heightened symptoms, including heavy menstrual flow (menorrhagia), significant monthly pain (dysmenorrhea), and moderate hormonal acne.

Lenea is applied across domains where additional symptomatic support is needed. It assists by supporting the establishment of more predictable, regular cycles. This support contributes to improved comfort during symptomatic periods, helping to ease the overall symptom load associated with both severe menstrual cramping and excessive menstrual bleeding. The medication may be part of symptomatic management for chronic, recurrent issues.


Quick Fact: Symptom Support Domains

This medication is relevant for easing symptoms that interfere with daily functioning, applied in contexts involving recurrent or episodic manifestations. It provides supportive relief when symptoms create noticeable physiological strain, assisting with maintaining hormonal consistency during difficult episodes.

Regulatory References

  1. National Library of Medicine's DailyMed database

Eligibility and Restrictions for Use

Lenea, a combined oral contraceptive containing estrogen and progestin, is prescribed for the prevention of pregnancy. Its use is generally intended for women of reproductive potential. However, it is contraindicated in several circumstances due to the risk of serious side effects, primarily related to thromboembolic events (blood clots).


Who Can Use Lenea?

  • Healthy women of reproductive age seeking effective contraception.
  • Individuals using it for non-contraceptive benefits under medical guidance, such as managing certain menstrual disorders.

Who Cannot Use Lenea? (Contraindications)

Lenea is not suitable for individuals with certain medical conditions or risk factors. This includes, but is not limited to, a history of:

Condition Category Specific Examples of Contraindications
Cardiovascular/Thromboembolic Deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, heart attack, or conditions that significantly increase the risk (e.g., severe uncontrolled high blood pressure, certain heart valve disorders, or an increased risk due to hereditary blood clotting disorders).
Hormone-Sensitive Cancers Known or suspected breast cancer or other estrogen- or progestin-dependent cancers.
Hepatic (Liver) Issues Active liver disease or benign or malignant liver tumors.
Other Undiagnosed abnormal uterine bleeding, certain types of severe migraine headaches (especially those with a focal aura), pregnancy or recent childbirth, and smoking if over 35 years old.

Lenea is not recommended for use during pregnancy, as birth control pills should be discontinued immediately if pregnancy occurs. For breastfeeding mothers, the decision to use Lenea should be made in consultation with a healthcare provider, considering the potential for the hormones to pass into breast milk.

What should I know about interactions with other medicines?

Lenea Interactions with other medicines and products

Interaction scope

Category Description
Medicinal product categories with documented interactions: Hepatic enzyme-inducing drugs (e.g., certain Anticonvulsants, Antibiotics), CYP1A2 substrates, Hepatitis C antiviral combinations.
Specific interacting medicines (if explicitly listed): Rifampin, Griseofulvin, Ombitasvir/Paritaprevir/Ritonavir, Glecaprevir/Pibrentasvir, Sofosbuvir/Velpatasvir/Voxilaprevir, Tizanidine, St John's wort (herbal product).
Mechanistic basis of interactions (only if stated in label): Antagonized by hepatic enzyme inducing drugs; Inhibition of Cytochrome P450 1A2 (CYP1A2) by Lenea resulting in increased plasma concentrations of co-administered drugs; Increased synthesis of Sex Hormone-Binding Globulin (SHBG).
Timing-based interaction rules (if applicable): A barrier method must be used during co-administration with enzyme-inducing drugs and for 28 days after discontinuation of the enzyme inducer.
Population-specific interaction notes (if applicable): Contraindicated in women over 35 years of age who smoke due to the increased risk of serious cardiovascular events with estrogen-containing contraceptives.
Interaction-related restrictions: Contraindicated with specific combination medicinal products used to treat Hepatitis C Virus (HCV) due to the risk of liver enzyme elevations (ALT).

Interaction classifications (high-level)

Category Description
Interaction severity classification (as defined in official documents): Contraindicated (HCV antivirals), Antagonized (Enzyme Inducers), Clinically Significant Increase in Exposure (e.g., Tizanidine).
Regulatory basis (EMA / FDA / etc.): Information is consistent with official labeling from the FDA (DailyMed) and EMA-aligned national health authority guidance concerning combined hormonal contraceptives.
Interaction-context constraints (as defined in official documents): Requirement to use an alternative contraceptive method when co-administering with certain enzyme-inducing medicines, including the herbal product St John's wort.

Resulting interaction structure

Official interaction statements:

  • Co-administration with specific Hepatitis C antiviral regimens (Ombitasvir/Paritaprevir/Ritonavir, Glecaprevir/Pibrentasvir, Sofosbuvir/Velpatasvir/Voxilaprevir) is formally contraindicated.
  • The contraceptive effect is officially antagonized by the use of hepatic enzyme-inducing drugs, which may increase the clearance of the active hormones.
  • Lenea can increase the plasma concentrations and effects of co-administered drugs that are metabolized by Cytochrome P450 1A2 (CYP1A2), such as Tizanidine.
  • The presence of Ethinyl Estradiol may affect the measurement of Sex Hormone-Binding Globulin (SHBG), altering the systemic concentration of other steroids.
  • Following the cessation of an enzyme-inducing medicine, a mandatory period of 28 days of barrier method contraception is required.

Connection to the overall interaction profile (2–4 sentences): The regulatory documents define Lenea's interaction profile primarily through pharmacokinetic alterations, where it is both a victim of decreased exposure due to enzyme induction and a perpetrator of increased exposure for other drugs via enzyme inhibition. The most stringent constraint is the classification of specific antiviral combinations as contraindicated due to high-risk liver-related interaction potential.

Mechanism of Action

How Lenea Works: Molecular Mechanism

Lenea (Lenalidomide) functions as a molecular glue that modifies the substrate specificity of the CRL4^ CRBN E3 ubiquitin ligase complex. The compound binds to cereblon (CRBN), a component of this ligase. This binding event alters the conformation of CRBN, enabling it to recruit and tag specific target proteins that were previously unrecognized by the enzyme.

The key recruited substrates include the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), and in some contexts, Casein Kinase 1A1 (CK1alpha). Once tagged with ubiquitin by the ligase, these proteins are marked for rapid destruction by the proteasome. The degradation of IKZF1 and IKZF3 disrupts key signaling pathways and modifies transcription in certain hematopoietic cells.

Simultaneously, Lenea modulates immune cell function. Its presence stimulates the proliferation and activation of T-cells and Natural Killer (NK) cells, enhancing immune-mediated cytotoxicity. These dual intracellular and immune-modulating cascades define its system-level physiological effect.

Dosage and Administration Information

How Lenea is Used: Official Administration Protocol

Lenea (Ethinyl Estradiol/Gestodene) is prescribed for oral administration only as a daily regimen. The usage protocol is structured around continuous 28-day cycles, typically consisting of 21 active hormone tablets followed by a seven-day hormone-free interval. The regimen requires taking one active tablet once daily at the same time every day to maintain a consistent dosing schedule.

Tablets are taken sequentially in the order indicated on the blister pack. The standard active dose is one tablet, delivering a fixed combination of hormones. Initial administration typically begins on the first day of the menstrual period (Day 1 Start). Tablets can be taken without regard to meals, although consistency in timing is essential.

Management of Dosing Deviation

If an active dose is missed by less than 12 hours, the tablet should be taken immediately, and contraceptive protection is maintained. If the tablet is missed by more than 12 hours, the standard protocol involves taking the last missed tablet immediately and using a non-hormonal barrier method for the following seven consecutive days. Additionally, if vomiting or severe diarrhea occurs within 3 to 4 hours of administration, the event must be treated as a missed tablet, necessitating adherence to the established protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lenea (Ethinyl Estradiol/Gestodene)


Evidence for Use in Reversible Contraception

Research for Lenea was studied for its use for the prevention of pregnancy. This area of study is supported by extensive research, including Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. Researchers examined core outcomes such as Contraceptive Efficacy, typically measured using the Pearl Index, and assessed Cycle Control by tracking the incidence and patterns of bleeding among participants over several cycles. Research was conducted primarily on women of childbearing potential.

Studies conducted during these periods of observation reported measurements of efficacy, which are described in regulatory summaries. Research describes that the formulation was studied for its ability to provide consistent hormonal regulation. Detecting meaningful differences in efficacy between this specific combination and other similar low-dose hormonal contraceptives is challenging due to the generally high reliability reported for these formulations.


Evidence for Use in Symptomatic Menstrual Conditions

Lenea was evaluated in research exploring its potential application in conditions characterized by periods of heightened symptom activity, specifically focusing on significant monthly pain (dysmenorrhea) and heavy menstrual flow (menorrhagia). The research here involves both RCTs and systematic reviews, with studies exploring short-term symptom changes.

For dysmenorrhea, research examined outcomes related to physical discomfort, such as changes in self-reported pain intensity scores and the frequency of painful days. For heavy menstrual flow, researchers explored how symptoms evolved in the observed populations by measuring blood loss and patient-reported charting over defined time intervals. Findings indicate patterns related to changes in flow amount and the achievement of greater cycle regularity in observed populations.


What is Still Uncertain About Lenea

The evidence, while robust for contraception, includes certain research limitation frames. The follow-up durations were limited in many of the key studies supporting non-contraceptive uses, meaning there is limited information for long-term outcomes or durability of these symptom patterns after extended use. Specifically, the comparative evidence is lacking for Lenea against placebo for several non-contraceptive indications, as studies often compare it only against other active treatments. Overall, research provides context but does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. DailyMed: Ethinyl Estradiol and Gestodene Tablets monograph (National Library of Medicine)
  2. Combined oral contraceptives for heavy menstrual bleeding (Cochrane Review)
  3. Oral contraceptives for acne vulgaris (Cochrane Review)

Frequently Asked Questions (FAQ)

Common questions about Lenea (FAQ)


Q: How is Lenea different from other treatments for the same condition?

Lenea is a combined hormonal contraceptive (CHC) containing a specific combination of Ethinyl Estradiol and the progestin Gestodene. Official documents categorize this formulation among combined oral contraceptives that have been associated with a slightly higher risk of venous thromboembolism (VTE) when compared to certain other formulations containing progestins such as levonorgestrel.


Q: How long does it typically take for Lenea to start working?

When initiating Lenea on the first day of the menstrual period (Day 1 Start), official information indicates that contraceptive protection is generally expected to be established after taking seven consecutive days of active tablets. Regulatory labeling indicates that a supplementary non-hormonal method is often noted as necessary during the first seven days of the initial cycle.


Q: Is Lenea safe for older adults?

Official studies on the effects of this medication combination have generally not included the geriatric (older adult) population. Lenea is primarily intended for women of reproductive potential. Official information states the drug is contraindicated for women over 35 years old who smoke due to the established increased risk of serious cardiovascular events.


Q: How do doctors monitor people taking Lenea?

Regulatory documents outline monitoring procedures recommended during Lenea use. This typically includes the regular monitoring of blood pressure, performing routine cervical smear tests, and checking for certain signs of vascular or liver issues periodically throughout the duration of use.


Q: Is Lenea a long-term or short-term treatment?

Lenea is prescribed as a continuous daily regimen structured around 28-day cycles. Its regulatory classification is for continuous systemic hormonal use, meaning it is typically intended to be used for as long as contraception is required and medical monitoring confirms continued eligibility.


Q: What if I feel Lenea is not working for me?

Official information emphasizes that the effectiveness of Lenea can be decreased if you experience severe vomiting or diarrhea within a few hours of administration, or if you co-administer it with certain enzyme-inducing medicines. If you have concerns about the drug's effectiveness, a consultation with a healthcare professional is noted as appropriate.


Q: Can Lenea affect my mood or sleep?

Yes, official safety documents list depressed mood and mood changes as common undesirable effects associated with Lenea use. Effects specifically on sleep are not explicitly listed in the very common or common adverse reaction categories.


Q: Can Lenea be cut or crushed?

The official product information describes Lenea as a film-coated tablet without a dividing score. The official documentation does not contain instructions for cutting or crushing the tablet, and the product is formulated for sequential oral administration.


Q: What is the risk of a severe allergic reaction to Lenea?

Official documents list hypersensitivity (a severe allergic reaction) as a rare adverse event. Official safety information states that the drug is contraindicated if a person is hypersensitive (allergic) to the active substances or any of the inactive ingredients.


Q: What are the signs that a side effect is serious?

Official warnings describe specific signs that necessitate urgent medical attention. These include unusual pain or swelling in the legs, stabbing pains when breathing, any significant rise in blood pressure, severe abdominal pain, or unusually severe and recurring headaches.


Q: What information should I read carefully before starting Lenea?

The most crucial information to review includes the full list of contraindications (who must not use the drug) and the serious warnings. Specifically, official documents highlight the Boxed Warning regarding the increased risk of serious cardiovascular events for women over 35 who smoke, as well as the detailed risk of venous thromboembolism (VTE).


Q: How does Lenea affect the immune system?

The defined mechanism of action describes Lenea as an immunomodulatory agent, meaning it affects the immune system. Specifically, it is described as stimulating the proliferation and activation of T-cells and Natural Killer (NK) cells, which is described as altering immune-mediated activity.


Q: Are the side effects of Lenea usually temporary?

Official patient information often indicates that many common and minor side effects, such as nausea, breast tenderness, or spotting, are most likely to occur during the first few months of use. These effects typically resolve gradually over time as the body adjusts to the medication.


Q: What should I expect the first few weeks after starting Lenea?

During the initial adjustment period, common effects reported include headache, nausea, breast tenderness, and some mood changes. It is also common to experience spotting or breakthrough bleeding in the first month, which typically subsides with continued use.


Q: Is it okay to drink coffee while on Lenea?

While specific warnings against common coffee consumption are not typically listed as a contraindication, certain regulatory texts note that caution may be warranted regarding caffeine intake. This is because certain components of the medication may interact with the way the body processes caffeine.


Q: Are there any age restrictions for taking Lenea?

Lenea is intended for use in women after they have started menstruating (after menarche). The drug is formally contraindicated for women over 35 years of age who smoke due to the heightened risk of serious cardiovascular events.


Q: Does Lenea require any special preparation before starting?

Official documents require certain physical and laboratory checks both before and during use, such as the monitoring of blood pressure and liver function tests. Beyond these medical checks, official instructions note the importance of proper pill sequence, including starting the next pack immediately after the hormone-free interval.


Q: Are there different versions or brands of Lenea?

The specific drug combination (Ethinyl Estradiol/Gestodene) is marketed globally under various different brand names. These different names may or may not contain slightly different dosages of the active components.


Q: Why do people sometimes stop taking Lenea?

Official documentation implies that discontinuation occurs either when a person decides contraception is no longer needed, or when serious adverse events (such as blood clots) or intolerable side effects (such as severe, recurring headaches or significant mood changes) occur.


Q: What if Lenea interacts with my blood pressure medicine?

Official warnings state that Lenea itself can cause or worsen high blood pressure (hypertension). This risk of a significant blood pressure increase during Lenea use is an official safety concern that may impact the required management of any co-administered blood pressure medication.


Q: Can Lenea be taken with cold and flu medicine?

Certain common components of cold and flu medicines, such as acetaminophen (paracetamol), may interact with the way the body processes Lenea. Official guidance indicates that for co-administration with new medications, review by a healthcare professional is noted to clarify potential interaction risks.


Q: Do studies show a high rate of success with Lenea?

Contraceptive effectiveness is officially measured using the Pearl Index. The data summarized by official documents indicate an efficacy rate of over 99% in clinical trials under conditions of perfect use.


Q: Is Lenea associated with any rare but serious conditions?

Yes, official safety documents list rare, serious conditions. These include Venous Thromboembolism (VTE) and Arterial Thromboembolism (ATE) (blood clots), along with certain serious liver function disturbances and the skin condition Erythema Multiforme.


Q: Can Lenea be taken on an empty stomach?

Official instructions generally state that the tablets may be taken with or without food. The most important instruction is to maintain consistency in the time of day the medication is administered.

How should Lenea be stored and disposed of?

How to Store and Dispose of Lenea?

The official storage and disposal requirements for Lenea are mandated by government regulatory agencies to ensure product stability and safety.

Official Storage Requirements

Storage Component Requirement (Based on Regulatory Labeling)
Temperature Store at a controlled temperature range, such as 20 C to 25 C.
Protection Keep in the original container to protect from light and moisture.
Security Store Lenea out of the sight and reach of children.
Stability Use or discard the product within a specified period (e.g., 30 days) after the container is first opened.

Official Disposal Rules

All unused or expired Lenea medication and associated waste material must be disposed of in accordance with local pharmaceutical regulatory requirements. Government instructions forbid disposing of the product via household wastewater or sewage, emphasizing the need for compliance with official drug take-back or hazardous waste programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lenea found in:

A-Z Index: